Low-FODMAP diet reduces irritable bowel symptoms in patients with inflammatory bowel disease

被引:138
作者
Pedersen, Natalia [1 ]
Ankersen, Dorit Vedel [2 ]
Felding, Maria [3 ]
Wachmann, Henrik [4 ]
Vegh, Zsuzsanna [5 ]
Molzen, Line [2 ]
Burisch, Johan [2 ]
Andersen, Jens Rikardt [3 ]
Munkholm, Pia [2 ]
机构
[1] Slagelse Hosp, Dept Gastroenterol, Ingemannsvej 24, DK-4200 Slagelse, Denmark
[2] North Zealand Hosp, Gastroenterol Unit, DK-3600 Frederikssund, Denmark
[3] Univ Copenhagen, Dept Nutr Exercise & Sports, DK-2100 Copenhagen, Denmark
[4] Larix AS, Dept Stat, DK-2730 Herlev, Denmark
[5] Semmelweis Univ, Dept Med 1, H-1083 Budapest, Hungary
关键词
inflammatory bowel disease; Web-based management; irritable bowel syndrome; Low-FODMAP diet; IBS-LIKE SYMPTOMS; QUALITY-OF-LIFE; FUNCTIONAL GASTROINTESTINAL SYMPTOMS; ULCERATIVE-COLITIS; CROHNS-DISEASE; FECAL CALPROTECTIN; ACTIVITY INDEX; PREVALENCE; REMISSION; VALIDATION;
D O I
10.3748/wjg.v23.i18.3356
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
AIM To investigate the effect of a low-FODMAP diet on irritable bowel syndrome (IBS)-like symptoms in patients with inflammatory bowel disease (IBD). METHODS This was a randomised controlled open-label trial of patients with IBD in remission or with mild-to-moderate disease and coexisting IBS-like symptoms (Rome III) randomly assigned to a Low-FODMAP diet (LFD) or a normal diet (ND) for 6 wk between June 2012 and December 2013. Patients completed the IBS symptom severity system (IBS-SSS) and short IBD quality of life questionnaire (SIBDQ) at weeks 0 and 6. The primary end-point was response rates (at least 50-point reduction) in IBS-SSS at week 6 between groups; secondary end-point was the impact on quality of life. RESULTS Eighty-nine patients, 67 (75%) women, median age 40, range 20-70 years were randomised: 44 to LFD group and 45 to ND, from which 78 patients completed the study period and were included in the final analysis (37 LFD and 41 ND). There was a significantly larger proportion of responders in the LFD group (n = 30, 81%) than in the ND group (n = 19, 46%); (OR = 5.30; 95% CI: 1.81-15.55, P < 0.01). At week 6, the LFD group showed a significantly lower median IBS-SSS (median 115; inter-quartile range [IQR] 33-169) than ND group (median 170, IQR 91-288), P = 0.02. Furthermore, the LFD group had a significantly greater increase in SIBDQ (median 60, IQR 51-65) than the ND group (median 50, IQR 39-60), P < 0.01. CONCLUSION In a prospective study, a low-FODMAP diet reduced IBS-like symptoms and increased quality of life in patients with IBD in remission.
引用
收藏
页码:3356 / 3366
页数:11
相关论文
共 45 条
[1]   Development and Validation of a Comprehensive Semi-Quantitative Food Frequency Questionnaire that Includes FODMAP Intake and Glycemic Index [J].
Barrett, Jacqueline S. ;
Gibson, Peter R. .
JOURNAL OF THE AMERICAN DIETETIC ASSOCIATION, 2010, 110 (10) :1469-1476
[2]   Predicting the Crohn's disease activity index from the Harvey-Bradshaw index [J].
Best, WR .
INFLAMMATORY BOWEL DISEASES, 2006, 12 (04) :304-310
[3]   East-West gradient in the incidence of inflammatory bowel disease in Europe: the ECCO-EpiCom inception cohort [J].
Burisch, J. ;
Pedersen, N. ;
Cukovic-Cavka, S. ;
Brinar, M. ;
Kaimakliotis, I. ;
Duricova, D. ;
Shonova, O. ;
Vind, I. ;
Avnstrom, S. ;
Thorsgaard, N. ;
Andersen, V. ;
Krabbe, S. ;
Dahlerup, J. F. ;
Salupere, R. ;
Nielsen, K. R. ;
Olsen, J. ;
Manninen, P. ;
Collin, P. ;
Tsianos, E. V. ;
Katsanos, K. H. ;
Ladefoged, K. ;
Lakatos, L. ;
Bjornsson, E. ;
Ragnarsson, G. ;
Bailey, Y. ;
Odes, S. ;
Schwartz, D. ;
Martinato, M. ;
Lupinacci, G. ;
Milla, M. ;
De Padova, A. ;
D'lnca, R. ;
Beltrami, M. ;
Kupcinskas, L. ;
Kiudelis, G. ;
Turcan, S. ;
Tighineanu, O. ;
Mihu, I. ;
Magro, F. ;
Barros, L. F. ;
Goldis, A. ;
Lazar, D. ;
Belousova, E. ;
Nikulina, I. ;
Hernandez, V. ;
Martinez-Ares, D. ;
Almer, S. ;
Zhulina, Y. ;
Halfvarson, J. ;
Arebi, N. .
GUT, 2014, 63 (04) :588-597
[4]   Deviations in human gut microbiota: a novel diagnostic test for determining dysbiosis in patients with IBS or IBD [J].
Casen, C. ;
Vebo, H. C. ;
Sekelja, M. ;
Hegge, F. T. ;
Karlsson, M. K. ;
Ciemniejewska, E. ;
Dzankovic, S. ;
Froyland, C. ;
Nestestog, R. ;
Engstrand, L. ;
Munkholm, P. ;
Nielsen, O. H. ;
Rogler, G. ;
Simren, M. ;
Ohman, L. ;
Vatn, M. H. ;
Rudi, K. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2015, 42 (01) :71-83
[5]   Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease [J].
D'Haens, Geert ;
Ferrante, Marc ;
Vermeire, Severine ;
Baert, Filip ;
Noman, Maja ;
Moortgat, Liesbeth ;
Geens, Patricia ;
Iwens, Doreen ;
Aerden, Isolde ;
Van Assche, Gert ;
Van Olmen, Gust ;
Rutgeerts, Paul .
INFLAMMATORY BOWEL DISEASES, 2012, 18 (12) :2218-2224
[6]   The low FODMAP diet improves gastrointestinal symptoms in patients with irritable bowel syndrome: a prospective study [J].
de Roest, R. H. ;
Dobbs, B. R. ;
Chapman, B. A. ;
Batman, B. ;
O'Brien, L. A. ;
Leeper, J. A. ;
Hebblethwaite, C. R. ;
Gearry, R. B. .
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2013, 67 (09) :895-903
[7]  
Drossman DA, 2000, AM J GASTROENTEROL, V95, P999
[8]   Characterization of health related quality of life (HRQOL) for patients with functional bowel disorder (FBD) and its response to treatment [J].
Drossman, Douglas ;
Morris, Carolyn B. ;
Hu, Yuming ;
Toner, Brenda B. ;
Diamant, Nicholas ;
Whitehead, William E. ;
Dalton, Christine B. ;
Leserman, Jane ;
Patrick, Donald L. ;
Bangdiwala, Shrikant I. .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2007, 102 (07) :1442-1453
[9]  
Drossman Douglas A, 2006, Chin J Dig Dis, V7, P181, DOI 10.1111/j.1443-9573.2006.00265.x
[10]   Functional gastrointestinal disorders and mood disorders in patients with inactive inflammatory bowel disease: Prevalence and impact on health [J].
Farrokhyar, F ;
Marshall, JK ;
Easterbrook, B ;
Irvine, EJ .
INFLAMMATORY BOWEL DISEASES, 2006, 12 (01) :38-46